On August 1, 2026, the regulatory framework governing pharmaceutical commercialization in China will undergo its most significant transformation in a decade. The new seven-department Medical Representative Management Measures (issued as National Medical Products Administration [NMPA] Announcement No. 42 of 2026, signed on April 28, 2026, and published on May 7, 2026) will take full effect. Jointly promulgated by the NMPA, the Ministry of Public Security (MPS), the National Health Commission (NHC), the State Administration for Market Regulation (SAMR), the National Healthcare Security Administration (NHSA), the National Administration of Traditional Chinese Medicine (NATCM), and the National Bureau of Disease Control and Prevention, these Measures establish a strict, cross-agency enforcement regime that effectively ends the era of sales-volume-driven field practices and shifts the commercialization paradigm to traceable, academic-only promotion.
For global biopharmaceutical manufacturers, Marketing Authorization Holders (MAHs), and their outsourced commercial partners, the countdown to August 1, 2026, demands an immediate overhaul of compliance policies, representative qualifications, and commercial contracting. Crucially, the Measures dismantle the traditional legal firewalls that MAHs historically built around third-party Contract Sales Organizations (CSOs) and outsourced professional services. Under the new rules, any promotion-related violation by an entrusted organization is directly attributable to the MAH.
This article provides an in-depth compliance playbook for global pharmaceutical executives, compliance officers, and market-access teams. It analyzes the major policy shifts, dissects the joint-agency regulatory structure, details the comprehensive 22 prohibited-behavior matrix across the supply chain, explains the new registration and portable filing requirements, and outlines the step-by-step transition plan that organizations must complete before the August 1, 2026, deadline. It sits within PharmaDossier's broader Asia regulatory-reform coverage and the wider set of China compliance obligations facing pharma.
What Changed: 2020 Trial Measures vs. 2026 Management Measures
The 2026 Management Measures comprise six chapters and 35 articles, completely replacing the Interim Measures for the Filing Administration of Pharmaceutical Representatives (Trial) issued by the NMPA in 2020. While the 2020 trial framework established the basic concept of a representative filing database, it lacked direct enforcement teeth, clear definitions of third-party liability, and cross-departmental alignment. The 2026 Measures correct these gaps by codifying a unified supervisory model and expanding the scope of compliance obligations.
The table below contrasts the regulatory requirements of the 2020 Trial Measures with the new standards set by the 2026 Management Measures.
| Regulatory Feature | 2020 Trial Measures | 2026 Management Measures (NMPA No. 42) |
|---|---|---|
| Issuing Authority | NMPA (Single Department) | Seven Joint Departments (NMPA, MPS, NHC, SAMR, NHSA, NATCM, Disease Control) |
| Hospital Access Gate | Consent-based (Hospital determines access rules) | Registration-based (Mandatory registration; identity verified against national platform) |
| CSO / Entrusted Org Liability | Unclear; liability primarily remained with the individual representative or local agency | Pierced; Article 12 strictly attributes entrusted CSO violations to the contracting MAH |
| Educational Threshold | No explicit academic degree requirement; recommended training | Mandatory junior-college (associate) degree or higher in medicine, pharmacy, or related fields |
| Filing Registry Scope | Basic demographic and employment status | Region-locked registry; includes compliance commitments and portable lifetime filing numbers |
| Prohibited Rep Behaviors | 7 primary prohibited acts | 9 primary prohibited acts (Article 24), backed by cross-agency prosecution |
| Medtech Applicability | Included in general definitions | Carved out; device personnel rules to be formulated separately (current application is forward-looking only) |
The transition from a consent-based hospital reception framework to a registration-based framework represents a profound shift. Under the 2020 system, healthcare institutions established their own internal policies to approve or deny rep visits. Under the 2026 Measures, a representative cannot promote or enter clinical areas unless they are formally filed on the national platform, registered at the specific healthcare institution, and verified in real-time. Hospitals are required to cross-check the representative’s credentials against the national filing platform, and they must deny entry if any discrepancy is found.
MAH Compliance Responsibility and the CSO Attribution Rule
The core legal mechanism of the 2026 Measures is the concentration of liability on the Marketing Authorization Holder (MAH). Historically, multinational pharmaceutical firms operating in China utilized complex distributor networks and domestic CSOs to insulate the global parent company from direct commercial-bribery risks. If a local distributor engaged in non-compliant behavior, the MAH could argue that the behavior violated corporate policy and was executed by an independent third party.
Articles 11 and 12 of NMPA Announcement No. 42 of 2026 dismantle this defense:
- Article 11 (MAH Primary Duty): The MAH bears ultimate responsibility for the behavior of its medical representatives. It must verify qualifications, conduct formal assessments, maintain training records, and actively audit the daily promotion activities of its representatives. Importantly, the MAH is explicitly barred from hiring, engaging, or authorizing any representative who has a commercial-bribery record in the national judicial or administrative database.
- Article 12 (Entrustment and CSO Attribution): When an MAH entrusts academic promotion to an external professional organization or CSO, the MAH must sign a formal, legally binding agreement that clearly defines compliance responsibilities and performance metrics. Crucially, the Measures state that the MAH cannot delegate its ultimate regulatory liability. If an entrusted CSO or its employed representative violates the representative code of conduct, the violation is legally attributed to the MAH.
This attribution rule means that global compliance teams must treat third-party CSOs with the same level of oversight as internal field forces. Due diligence can no longer be a checkbox exercise; it must include continuous auditing, real-time transaction monitoring, and the insertion of immediate termination clauses in CSO agreements. Furthermore, the CSO’s authorization letter (issued by the MAH) is now a statutory prerequisite for filing representatives on the national platform. Without this formal link, the CDE (Center for Drug Evaluation) and NMPA database will refuse to issue a registration number.
The 22-Act Prohibited Behavior Matrix
The 2026 Measures outline a strict set of prohibitions designed to eliminate commercial bribery, prescription-tallying (commonly known as fangfang in Chinese clinical settings), and unauthorized promotional claims. By combining the restrictions placed on MAHs, entrusted organizations, individual representatives, and medical institutions, the framework establishes a 22 prohibited-act matrix.
The matrix below organizes these 22 prohibitions across the four primary target groups defined in Articles 11, 12, 24, and 25 of the Measures.
=======================================================
| CHINA 2026 MEDICAL REPRESENTATIVE PROHIBITIONS |
=======================================================
|
---------------------------------------------------------------------------------
| | | |
[MAH Duties (4)] [Entrusted Orgs (4)] [Reps (9)] [Institutions (5)]
(Article 11) (Article 12) (Article 24) (Article 25)
| | | |
1. No bribery-record reps 1. No sub-entrusting 1. No sales 1. No unregistered
2. Mandatory training without MAH OK targets rep reception
3. Annual audit trails 2. No unauthorized materials 2. No payment 2. No prescription-
4. Immediate filing updates 3. No undisclosed sub-agents handling tallying data
4. Joint audit compliance 3. No tallying 3. No clinical area
prescriptions unauthorized visits
4. No disguised 4. No commercial
benefits bribery reception
5. No off-label 5. Strict audit
promotion trail reports
6. No safety
concealments
7. No fake/unapproved
materials
8. No patient/clinical
info collection
9. No unfiled/unauth
activities
1. Marketing Authorization Holder Prohibitions (Article 11 — 4 Acts)
- Hiring/Authorizing Representatives with Bribery Records: The MAH must check judicial and administrative records; hiring or authorizing anyone with a commercial-bribery history is strictly prohibited.
- Failing to Maintain Training and Assessment Records: The MAH cannot deploy a representative without completing formal compliance training, academic testing, and retaining the audit trail.
- Omitting Routine Compliance Auditing: The MAH is prohibited from operating without a documented, annual internal audit process covering representative activities and expenses.
- Neglecting Filing Database Accuracy: The MAH must not leave stale or inaccurate data in the national filing system; changes in representative status, region, or employment must be updated promptly to keep the public record accurate.
2. Entrusted Professional Organization / CSO Prohibitions (Article 12 — 4 Acts)
- Sub-Entrusting Promotion: A CSO cannot delegate or sub-contract its academic promotion duties to another third party without the explicit, written authorization of the MAH.
- Using Non-Approved Materials: The entrusted organization is barred from using promotional slides, brochures, or clinical data that have not been formally reviewed and approved by the MAH.
- Employing Undisclosed Sub-Agents: The CSO must not utilize freelancers or independent contractors who are not formally registered on the national database as affiliated with the CSO and the underlying MAH.
- Obstructing Audit Compliance: The CSO is prohibited from refusing to disclose expense details, representative travel logs, or academic meeting records during audits conducted by the MAH or regulatory agencies.
3. Medical Representative Prohibitions (Article 24 — 9 Acts)
The individual representative is the focal point of field compliance. Article 24 lists nine prohibited behaviors that must be monitored through digital compliance platforms: 9. Carrying Sales Targets: Medical representatives are strictly barred from participating in sales-quota allocations or carrying direct sales volume/target metrics. 10. Collecting or Handling Payments: Representatives must not collect, handle, or facilitate any financial transactions, payments, or invoices for drug procurement. 11. Tallying Prescriptions: Representatives are prohibited from collecting, compiling, or accessing clinical prescription data (e.g., counting how many times a specific doctor prescribed a drug). 12. Offering Disguised Benefits: Offering rebates, kickbacks, entertainment, personal gifts, or disguised academic sponsorships to healthcare professionals (HCPs) is strictly banned. 13. Off-Label and Out-of-Scope Promotion: Promoting indications, dosages, or patient populations not approved in the official NMPA-cleared drug label is prohibited. 14. Concealing Adverse Reactions: Representatives must not hide, downplay, or fail to report adverse drug reactions or safety signals discovered in clinical practice. 15. Distributing Unapproved Materials: Presenting clinical reports, trial summaries, or pamphlets that have not received internal MAH medical-affairs approval is barred. 16. Illegally Collecting Patient/Institution Information: Representatives are prohibited from collecting patient diagnostic records, genetic data, or healthcare institution statistics without legal consent. 17. Promoting Outside Authorized Scope: Engaging in promotion activities outside the specific geographical region, product line, or time window authorized in the official MAH filing is banned.
4. Healthcare Institution and Medical Staff Prohibitions (Article 25 — 5 Acts)
- Unregistered Representative Reception: Hospitals must not host or allow visits from representatives who are not registered in the hospital's internal database.
- Providing Prescription-Tallying Data: Medical staff are prohibited from disclosing prescription statistics or electronic health record (EHR) outputs to representatives.
- Allowing Unauthorized Clinical Area Visits: Clinicians and administrators must not permit representatives to enter outpatient consultation rooms, inpatient wards, or pharmacies during working hours.
- Accepting Disguised Commercial Bribery: Healthcare staff are barred from accepting personal travel, speaker fees without legitimate academic work, or gifts.
- Failing to Document Visits: Hospital compliance departments must not permit visits without creating a permanent audit trail detailing the date, rep name, filing number, and discussed topic.
Hospital Reception, Registration, and Filing-Number Rules
The new framework establishes a strict digital link between the national database, the MAH, the representative, and the hospital. In practice, the compliance workflow operates under the following rules:
The Lifetime Portable Filing Number
Every medical representative who meets the educational threshold (junior-college degree or higher in medicine, pharmacy, or related fields) must submit their credentials to the NMPA national filing platform. Upon validation, the platform issues a lifetime filing number. This number functions as a professional passport. If a representative changes employers (e.g., moving from one MAH to another), the individual does not get a new number. Instead, the new MAH must log into the system, claim the representative, upload the new training and assessment record, and link the existing number to the new corporate entity. The record of the previous employment remains visible in the system, creating a permanent, traceable career history.
Region-Locks and Geographical Boundaries
A key anti-arbitrage feature of the 2026 Measures is the region-lock. When filing a representative, the MAH must declare the specific province and municipal region where the representative is authorized to conduct academic promotion. A representative filed for Sichuan Province, for example, is legally barred from promoting products in Guangdong Province. If a representative is found conducting a seminar or visiting a hospital outside their registered region, it is treated as an unauthorized promotion activity under Article 24 (Prohibition 9), exposing both the representative and the MAH to immediate enforcement action.
The Hospital Registration and Verification Gate
Under Article 25, healthcare institutions must implement a "three-lock" reception control:
- Pre-Registration: Before visiting a hospital, the representative must submit their national filing number, ID, MAH authorization letter, and proof of training to the hospital's compliance or equipment administration office.
- Verification: The hospital verifies the representative's identity against the national NMPA filing platform (the official interpretation confirms that where identity information does not match the filed record, the institution must not receive the representative). If the representative’s status is "inactive," if their authorized region does not match the hospital's location, or if their listed MAH does not match the product they are promoting, the registration is rejected.
- Reception Record: Once verified, visits are restricted to designated administrative meeting rooms (reception rooms) during specified hours. Clinical areas (outpatient clinics, inpatient wards, drug testing labs) are off-limits. The hospital must record every visit, compile an annual log, and submit it to the local health commission.
=============================================================================
HOSPITAL ACCESS & VERIFICATION FLOW
=============================================================================
[ Medical Representative ]
│
▼
1. Submit National Filing Number & ID to Hospital Compliance Office
│
▼
2. Hospital System Queries National NMPA Platform API
│
┌────┴─────────────────────────┐
▼ (Verification) ▼ (Verification)
[ MATCHED ] [ MISMATCH / INACTIVE ]
│ │
▼ ▼
3. Check Regional Lock Entry Rejected
(e.g., Province match) (Reported to Health Commission)
│
├──────────────────────────────┐
▼ (Match) ▼ (Mismatch)
4. Issue Temp Access Badge Entry Rejected
│
▼
5. Academic Promotion in
Designated Reception Room Only
(Clinics/Wards Off-Limits)
│
▼
6. Hospital Records Visit Detail
(Permanent Audit Trail)
=============================================================================
Practical Operating Model Implementation Guide for MAHs
To achieve compliance before the August 1, 2026, cutover date, global pharmaceutical companies must transition from a reactive policy model to a proactive, evidence-based operating system. Compliance teams should implement the following three-pillar playbook:
Pillar 1: Contract Re-Papering and CSO Risk Allocation
Every distributor, CSO, and marketing agency agreement must be audited and revised. The discipline is the same outsourced-party contracting and red-flag screening used for CDMO quality agreements, now applied to the promotion chain. Legal teams must draft specific addenda that reflect the attribution rules of Article 12:
- Compliance Covenants: Incorporate the 22-act prohibited behavior matrix directly into the contract as material terms. A breach of any single item must trigger immediate, unilateral termination rights without cure periods.
- Anti-Bribery Indemnification: CSOs must provide full financial indemnification for any administrative fines, litigation expenses, or loss of market-access rights suffered by the MAH due to CSO-related violations.
- Audit Rights: Secure unrestricted, real-time access to the CSO's financial ledgers, employee expense reports, travel data, and training records. MAHs should run quarterly random audits on CSO field teams.
Pillar 2: Credential Auditing and Database Management
Global MAHs must audit their existing field forces to ensure compliance with the new educational and training standards:
- Educational Audit: Collect and verify diploma records for all in-house and contracted representatives. Representatives who do not hold a junior-college (associate) or higher degree in medicine, pharmacy, or a related field must be transitioned out of promotion roles before August 1, 2026.
- Training & Testing Roster: Establish a standardized academic and compliance testing protocol. Every representative must pass a formal assessment covering product safety, NMPA-approved indications, and Chinese anti-bribery laws. Retain these digital certificates as statutory audit trails.
- Filing Update Window: Dedicate a registry team to upload and synchronize representative data on the national platform. Ensure all changes (transfers, resignations, region modifications) are logged promptly, since hospitals verify reps against the live public record.
Pillar 3: Field Force Digital Monitoring and Control
Field operations must be monitored through verified digital systems to prevent high-risk behaviors:
- GPS and Check-In Controls: Field reps should use enterprise applications that require GPS check-in at authorized hospital reception locations, preventing unauthorized visits to clinical wards.
- Sales Target Separation: Finance and HR must review compensation plans. Representatives must be evaluated on academic meeting quality, HCP training metrics, and compliance audits—not on individual sales quotas or regional prescription volumes.
- Expense Substantiation: Every promotional expense (e.g., academic dinner, seminar refreshments) must be linked to a verified, registered hospital visit or academic meeting ID. Receipts must be cross-checked against the hospital reception log.
Enforcement, Credit Blacklists, and Market Access Risks
The inclusion of the NHSA, SAMR, and MPS as joint issuing authorities signals a coordinated enforcement strategy that connects representative compliance directly to market access and criminal prosecution.
Cross-Agency Enforcement Workflow
Under the new rules, if NHC hospital audits detect a representative tallying prescriptions or distributing unapproved materials:
- Administrative Referral: The NHC refers the case to the SAMR (for commercial bribery or unfair competition) and the NMPA (for filing violations).
- NHSA Drug Price and Procurement Credit System: If commercial bribery is confirmed, the SAMR transmits the ruling to the NHSA. The NHSA applies the Drug Price and Procurement Credit Rating System, which ranks companies based on compliance.
- Credit Ratings and Procurement Exclusions: A "Serious" or "Very Serious" credit rating triggers immediate exclusion from provincial public procurement bidding, centralized drug procurement (GPO), and the National Reimbursement Drug List (NRDL) negotiation process.
- Criminal Referral: If the financial thresholds for commercial bribery are met, the MPS initiates criminal investigations against both the individual representatives and the MAH executives who failed to supervise them.
Real-World Enforcement Context
This coordinated enforcement is backed by existing regulatory campaigns. By the end of 2025, Sichuan Province alone reported revoking the registrations of 2,061 non-compliant representatives under preliminary local trials of the database system. Nationally, there are approximately 116,000 filed representatives and 2,000+ MAHs registered on the NMPA platform. Regulatory experts predict that the NMPA and NHC will initiate national joint campaigns in the autumn of 2026 to audit hospital reception logs against the national database, aiming to remove unregistered and unqualified personnel from the healthcare system.
Frequently Asked Questions (FAQ)
Do already-filed medical representatives need to re-file before August 1, 2026?
Yes. Already-filed representatives do not lose their lifetime filing numbers, but their records must be updated to meet the new 2026 standards. The MAH must verify that all active representatives have their educational diplomas uploaded, their regional scopes defined, and their compliance training records linked to their profile. Failure to update the profiles before August 1, 2026, will result in the representative's status being marked as "inactive," which will block hospital access verification.
Can a CSO's violation really be attributed to the marketing authorization holder?
Yes, absolutely. Under Article 12 of the 2026 Management Measures, the MAH cannot contract away its regulatory liability. If a third-party CSO or its representative engages in commercial bribery, off-label promotion, or prescription-tallying while promoting the MAH's products, the NMPA and SAMR will hold the MAH legally responsible. This can result in fines for the MAH, the revocation of the drug's marketing authorization, and a downgrade in the NHSA pricing credit system.
Does the 2026 No. 42 rule apply to medical-device sales representatives today?
No. NMPA Announcement No. 42 of 2026 explicitly states that the measures governing medical-device enterprise personnel who conduct academic promotion and product demonstrations in medical institutions will be formulated separately. Therefore, the implications for medtech companies are forward-looking only. However, medical-device manufacturers should watch this space closely, as the NMPA is expected to issue a nearly identical framework for device representatives in late 2026 or early 2027.
Sources
- National Medical Products Administration (NMPA). Announcement on the Issuance of the Medical Representative Management Measures (No. 42 of 2026). Jointly issued by NMPA, MPS, NHC, SAMR, NHSA, NATCM, and the National Bureau of Disease Control and Prevention. Signed April 28, 2026; Published May 7, 2026; Effective August 1, 2026. NMPA Announcement No. 42 of 2026
- China Center for Food and Drug International Exchange (CCFDIE). Official Policy Interpretation: Medical Representative Management Measures. NMPA. Published May 7, 2026. CCFDIE Policy Interpretation
- Arnold & Porter. China Strengthens Management of Medical Representatives. Perspectives & Advisories. Published June 2026. Arnold & Porter Advisory
- Morgan Lewis & Bockius LLP. China Steps Up Anti-Corruption Enforcement with New Regulatory Frameworks. Law Flash. Published May 2026. Morgan Lewis Law Flash
- Hogan Lovells. China's Medical Insurance Enforcement in 2026: New Rules, Active Campaign, and Implications. Hogan Lovells Publications. Published 2026. Hogan Lovells Publication
- Cisema. China Issues Revised Measures Governing Pharmaceutical Representatives and Academic Promotion Activities. Industry News. Published June 1, 2026. Cisema Industry News
- Dacheng Law Offices. Legal Interpretation of the Entrusted Promotion Rules under the 2026 Medical Rep Measures. Dacheng Shanghai. Published May 2026. Dacheng Legal Analysis
- AllBright Law Offices. From 2020 to 2026: Evolution and Compliance Matrix of Medical Representative Management. AllBright Insights. Published June 2026. AllBright Legal Insights
- U.S. Food and Drug Administration (FDA). Office of Prescription Drug Promotion (OPDP) Bad Ad Program. FDA OPDP Bad Ad Program
